What age can you take Mounjaro, and who actually qualifies?

Step 1: The minimum age rule — and why under-18s are excluded

Tirzepatide has not been studied in children or adolescents. The clinical trials that led to Mounjaro's UK weight-management licence enrolled adults only, which means the safety and effectiveness data simply do not exist for younger people. Because of that, the Medicines and Healthcare products Regulatory Agency authorised Mounjaro for adults aged 18 and above, and no prescriber operating within that licence can issue it to someone younger.

One misconception that surfaces regularly is the idea that a high BMI might create an exception for a 16 or 17-year-old. It does not. The age threshold is fixed in the licence, full stop. Weight-related health concerns in under-18s are real and important, but the right pathway involves a GP and specialist paediatric services, not a GLP-1 medicine licenced for adults. If you are looking for guidance on options in that age range, the tirzepatide overview explains the licensed position clearly.

At the other end of the age range, there is no upper cut-off. A 70-year-old with a BMI of 32 and hypertension is not excluded by age alone. That said, prescribers take a more detailed look at kidney function, existing medicines, and frailty in older adults, because both Mounjaro and the GI side effects that can accompany it (nausea, reduced appetite, dehydration risk) carry greater practical significance when someone is older or on multiple medications. For a full breakdown of the exact age criteria that apply, our guide on what age you can use Mounjaro sets out the rules in plain terms.

Step 2: BMI and health conditions — the two-track eligibility route

Once the age threshold is met, eligibility splits into two routes set out in the UK licence and reinforced by NICE's appraisal of tirzepatide (TA1026).

The first route is a BMI of 30 or above. The second is a BMI of 27 to 29.9 alongside at least one weight-related condition, things like type 2 diabetes, high blood pressure, dyslipidaemia, or obstructive sleep apnoea. Lower BMI thresholds (2.5 kg/m² below the standard figures) apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, reflecting established differences in metabolic risk at a given BMI.

A useful first check is the NHS BMI calculator, which gives a quick read of where you sit. BMI is only a starting point, though. The prescriber's clinical review covers health history, current medicines, contraindications, and whether any conditions make Mounjaro unsuitable despite the numbers adding up on paper.

If you are thinking about cost alongside eligibility, the Mounjaro pricing page explains what a private prescription typically includes in the UK and what drives variation between providers.

Step 3: What happens during the clinical assessment at any age

The word "assessment" is worth taking literally. At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not a decision tree) on the same day it arrives. That review considers age and BMI, but also a photo-verified identity check, a live video weight verification, a full medication review, and (where relevant) a Summary Care Record check.

Certain conditions prompt extra caution at any age: a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, and some gastrointestinal conditions. Pregnancy, breastfeeding, and actively trying to conceive are all situations where Mounjaro is not recommended; women of childbearing age who use oral contraceptives are also advised to add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because Mounjaro's effect on gastric emptying can reduce pill absorption. The full detail on side effects and contraindications is covered on the what Mounjaro can cause page.

For patients already on treatment elsewhere, dose increases require evidence of the previous dose before a prescriber will move the prescription up. Transfer patients provide that evidence at consultation. Our clinical team applies the same standard to every case, 18 or 68.

Older adults: practical considerations worth knowing

There is a reasonable concern among people in their 60s and 70s about whether GLP-1 treatment is appropriate for them, and it is worth addressing directly. The licence does not exclude older adults. Clinical trial populations did include participants in older age groups, and weight-related conditions (cardiovascular risk, type 2 diabetes, sleep apnoea) become more common, not less, with age.

What changes with age is the risk-benefit conversation. Muscle mass tends to decline naturally from midlife onwards, and meaningful weight loss accelerates that process if protein intake and resistance activity are not prioritised. A prescriber will factor this in. Kidney function matters too: reduced renal clearance can affect how medicines behave and increase vulnerability to dehydration if GI side effects are pronounced. None of this rules Mounjaro out for older patients, but it shapes the clinical discussion.

If you are curious about what the evidence shows beyond the age eligibility question, the broader Mounjaro treatment guide covers how the medicine works, the trial results, and what ongoing monitoring looks like. Or if you are ready to see whether you qualify, you can speak to our prescribers through a free consultation, reviewed the same working day. You may also find it helpful to read about Mounjaro IK, which explains the specific formulation details relevant to UK prescriptions.